Literature DB >> 6549120

Antimicrobial activities of BMY-28142, cefbuperazone, and cefpiramide compared with those of other cephalosporins.

N J Khan, J A Bihl, R F Schell, J L LeFrock, S J Weber.   

Abstract

The antimicrobial activities of BMY-28142, cefbuperazone (BMY-25182; formerly T-1982), and cefpiramide (WY-44635; formerly SM-1652) were compared with those of cefmenoxime, cefoperazone, cefotaxime, ceftizoxime, and moxalactam. BMY-28142 was the most active cephalosporin against the majority of aerobic and facultatively anaerobic microorganisms studied. Its spectrum of activity was very similar to that of cefotaxime. However, BMY-28142, cefbuperazone, cefmenoxime, cefotaxime, ceftizoxime, and moxalactam were equivalent in activity and rate of killing against members of the family Enterobacteriaceae. Cefpiramide was considerably less active than the other cephalosporins against the Enterobacteriaceae.

Entities:  

Mesh：

Substances：

Year:  1984        PMID： 6549120      PMCID： PMC179970          DOI： 10.1128/AAC.26.4.585

Source DB:  PubMed          Journal:  Antimicrob Agents Chemother        ISSN： 0066-4804            Impact factor:   5.191


  18 in total

1.  Comparative in vitro activity of moxalactam, cefotaxime, cefoperazone, piperacillin, and aminoglycosides against gram-negative bacilli.

Authors:  T O Kurtz; D J Winston; J A Hindler; L S Young; W L Hewitt; W J Martin
Journal:  Antimicrob Agents Chemother       Date:  1980-10       Impact factor: 5.191

Review 2.  Third-generation and investigational cephalosporins: I. Structure-activity relationships and pharmacokinetic review.

Authors:  P Garzone; J Lyon; V L Yu
Journal:  Drug Intell Clin Pharm       Date:  1983 Jul-Aug

3.  In vitro antibacterial activity of SM-1652, a new broad-spectrum cephalosporin with antipseudomonal activity.

Authors:  M Fukasawa; H Noguchi; T Okuda; T Komatsu; K Yano
Journal:  Antimicrob Agents Chemother       Date:  1983-02       Impact factor: 5.191

Review 4.  The new beta-lactamase-stable cephalosporins.

Authors:  H C Neu
Journal:  Ann Intern Med       Date:  1982-09       Impact factor: 25.391

5.  In vitro and in vivo antibacterial activity of T-1982, a new semisynthetic cephamycin antibiotic.

Authors:  M Tai; Y Fukuoka; A Yotsuji; K Kumano; M Takahata; H Mikami; T Yasuda; I Saikawa; S Mitsuhashi
Journal:  Antimicrob Agents Chemother       Date:  1982-11       Impact factor: 5.191

6.  In vitro antibacterial activity of cefpiramide.

Authors:  M A Pfaller; A C Niles; P R Murray
Journal:  Antimicrob Agents Chemother       Date:  1984-03       Impact factor: 5.191

7.  Comparison of cefoperazone, cefotaxime, and moxalactam (LY127935) against aerobic gram-negative bacilli.

Authors:  S D Lang; D J Edwards; D T Durack
Journal:  Antimicrob Agents Chemother       Date:  1980-03       Impact factor: 5.191

8.  Antibacterial activities of SM-1652 compared with those of other broad-spectrum cephalosporins.

Authors:  M Kato; M Inoue; S Mitsuhashi
Journal:  Antimicrob Agents Chemother       Date:  1982-11       Impact factor: 5.191

9.  Comparative in vitro study in new cephalosporins.

Authors:  G P Bodey; V Fainstein; A M Hinkle
Journal:  Antimicrob Agents Chemother       Date:  1981-08       Impact factor: 5.191

Review 10.  Mechanism of action, antimicrobial activity, pharmacology, adverse effects, and clinical efficacy of cefotaxime.

Authors:  J L LeFrock; R A Prince; R D Leff
Journal:  Pharmacotherapy       Date:  1982 Jul-Aug       Impact factor: 4.705
View more
  19 in total

1.  Modulation of the intestinal flora of mice by parenteral treatment with broad-spectrum cephalosporins.

Authors:  M L van Ogtrop; H F Guiot; H Mattie; R van Furth
Journal:  Antimicrob Agents Chemother       Date:  1991-05       Impact factor: 5.191

2.  Comparative activity of cefepime, alone and in combination, against clinical isolates of Pseudomonas aeruginosa and Pseudomonas cepacia from cystic fibrosis patients.

Authors:  J A Bosso; B A Saxon; J M Matsen
Journal:  Antimicrob Agents Chemother       Date:  1991-04       Impact factor: 5.191

3.  In vitro activity and stability against novel beta-lactamases of investigational beta-lactams (cefepime, cefpirome, flomoxef, SCE2787 and piperacillin plus tazobactam) in comparison with established compounds (cefotaxime, latamoxef and piperacillin).

Authors:  A Bauernfeind; S Schweighart; E Eberlein; R Jungwirth
Journal:  Infection       Date:  1991       Impact factor: 3.553

4.  Tentative disk diffusion susceptibility interpretive criteria for BMY-28142, a new cephalosporin.

Authors:  P C Fuchs; R N Jones; A L Barry; C Thornsberry
Journal:  J Clin Microbiol       Date:  1986-03       Impact factor: 5.948

5.  High hepatic excretion in humans of cefpiramide, a new cephalosporin.

Authors:  J M Brogard; F Jehl; M Adloff; J F Blickle; H Monteil
Journal:  Antimicrob Agents Chemother       Date:  1988-09       Impact factor: 5.191

6.  Efficacy of BMY-28142 in experimental bacteremia and meningitis caused by Escherichia coli and group B streptococci.

Authors:  K S Kim; A S Bayer
Journal:  Antimicrob Agents Chemother       Date:  1985-07       Impact factor: 5.191

7.  Evaluation of the in vitro activity of BMY-28142, a new broad-spectrum cephalosporin.

Authors:  P C Fuchs; R N Jones; A L Barry; C Thornsberry
Journal:  Antimicrob Agents Chemother       Date:  1985-05       Impact factor: 5.191

8.  Respiratory superinfections after the use of third-generation cephem antibiotics.

Authors:  A Saito; K Mori; Y Shigeno; K Yamaguchi; K Hara
Journal:  Infection       Date:  1985       Impact factor: 3.553

9.  Comparative in vitro activity of cefepime (BMY 28142) against multiresistant nosocomial isolates of Pseudomonas aeruginosa.

Authors:  D Voutsinas; T Mavroudis; A Avlamis; H Giamarellou
Journal:  Eur J Clin Microbiol Infect Dis       Date:  1989-10       Impact factor: 3.267

Review 10.  Cefepime clinical pharmacokinetics.

Authors:  M P Okamoto; R K Nakahiro; A Chin; A Bedikian
Journal:  Clin Pharmacokinet       Date:  1993-08       Impact factor: 6.447
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.